Major histocompatibility complex (MHC) class I molecules are key in the immune response against malignant cells by shaping the T-cell repertoire and presenting peptides from endogenous antigens to CD8+ cytotoxic T cells. Because of their unique specificity, MHC-peptide complexes are a desirable target for novel immunotherapeutic approaches. These complexes can be targeted by recombinant T-cell receptors (TCRs). However, most TCRs produced thus far have affinities which are too low for target detection under normal assay conditions, and limited stability (due to their generation in a single-chain version). Developing high-affinity soluble antibody molecules endowed with a TCR-like specificity toward tumor epitopes, termed TCR-like antibodies, addresses the low affinity of TCRs. These TCR-like antibodies are being developed as a new immunotherapeutic class for targeting tumor cells and mediating their specific killing. In addition, these antibodies are valuable research reagents enabling the study of human class I peptide-MHC ligand-presentation and TCR–peptide–MHC interactions.
References
[1]
Boon, T.; van der Bruggen, P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 1996, 183, 725–729, doi:10.1084/jem.183.3.725.
[2]
Renkvist, N.; Castelli, C.; Robbins, P.F.; Parmiani, G. A listing of human tumor antigens recognized by T cells. Cancer Immunol. Immunother. 2001, 50, 3–15, doi:10.1007/s002620000169.
[3]
Rosenberg, S.A. Progress in human tumour immunology and immunotherapy. Nature 2001, 411, 380–384, doi:10.1038/35077246.
[4]
Anichini, A.; Maccalli, C.; Mortarini, R.; Salvi, S.; Mazzocchi, A.; Squarcina, P.; Herlyn, M.; Parmiani, G. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic t cell clones from melanoma patients. J. Exp. Med. 1993, 177, 989–998, doi:10.1084/jem.177.4.989.
[5]
Coulie, P.G.; Brichard, V.; Van Pel, A.; Wolfel, T.; Schneider, J.; Traversari, C.; Mattei, S.; De Plaen, E.; Lurquin, C.; Szikora, J.P.; et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 1994, 180, 35–42, doi:10.1084/jem.180.1.35.
[6]
Shetty, V.; Sinnathamby, G.; Nickens, Z.; Shah, P.; Hafner, J.; Mariello, L.; Kamal, S.; Vlahovic, G.; Lyerly, H.K.; Morse, M.A.; et al. MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response. J. Proteomics 2011, 74, 728–743, doi:10.1016/j.jprot.2011.02.020.
[7]
Wang, Z.; Marincola, F.M.; Rivoltini, L.; Parmiani, G.; Ferrone, S. Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624mel28 melanoma cells. J. Exp. Med. 1999, 190, 205–215, doi:10.1084/jem.190.2.205.
[8]
Offringa, R.; van der Burg, S.H.; Ossendorp, F.; Toes, R.E.; Melief, C.J. Design and evaluation of antigen-specific vaccination strategies against cancer. Curr. Opin. Immunol. 2000, 12, 576–582, doi:10.1016/S0952-7915(00)00145-X.
[9]
Nagaraj, S.; Gabrilovich, D.I. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res. 2008, 68, 2561–2563, doi:10.1158/0008-5472.CAN-07-6229.
[10]
Klenerman, P.; Cerundolo, V.; Dunbar, P.R. Tracking T cells with tetramers: New tales from new tools. Nat. Rev. Immunol. 2002, 2, 263–272, doi:10.1038/nri777.
[11]
Novellino, L.; Castelli, C.; Parmiani, G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother. 2005, 54, 187–207, doi:10.1007/s00262-004-0560-6.
[12]
Morin, P.J.; Sparks, A.B.; Korinek, V.; Barker, N.; Clevers, H.; Vogelstein, B.; Kinzler, K.W. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, 275, 1787–1790, doi:10.1126/science.275.5307.1787.
[13]
de Vries, T.J.; Fourkour, A.; Wobbes, T.; Verkroost, G.; Ruiter, D.J.; van Muijen, G.N. Heterogeneous expression of immunotherapy candidate proteins gp100, mart-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res. 1997, 57, 3223–3229.
[14]
Nakada, T.; Noguchi, Y.; Satoh, S.; Ono, T.; Saika, T.; Kurashige, T.; Gnjatic, S.; Ritter, G.; Chen, Y.T.; Stockert, E.; et al. Ny-eso-1 mrna expression and immunogenicity in advanced prostate cancer. Cancer Immun. 2003, 3, 10.
[15]
Sugita, Y.; Wada, H.; Fujita, S.; Nakata, T.; Sato, S.; Noguchi, Y.; Jungbluth, A.A.; Yamaguchi, M.; Chen, Y.T.; Stockert, E.; et al. Ny-eso-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res. 2004, 64, 2199–2204, doi:10.1158/0008-5472.CAN-03-3070.
[16]
King, C.R.; Kraus, M.H.; Aaronson, S.A. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985, 229, 974–976.
[17]
Schechter, A.L.; Stern, D.F.; Vaidyanathan, L.; Decker, S.J.; Drebin, J.A.; Greene, M.I.; Weinberg, R.A. The neu oncogene: An erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984, 312, 513–516, doi:10.1038/312513a0.
[18]
Esche, C.; Shurin, M.R.; Lotze, M.T. The use of dendritic cells for cancer vaccination. Curr. Opin. Mol. Ther. 1999, 1, 72–81.
[19]
Kugler, A.; Stuhler, G.; Walden, P.; Zoller, G.; Zobywalski, A.; Brossart, P.; Trefzer, U.; Ullrich, S.; Muller, C.A.; Becker, V.; et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med. 2000, 6, 332–336, doi:10.1038/73193.
[20]
Andersen, P.S.; Stryhn, A.; Hansen, B.E.; Fugger, L.; Engberg, J.; Buus, S. A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Proc. Natl. Acad. Sci. USA 1996, 93, 1820–1824, doi:10.1073/pnas.93.5.1820.
Denkberg, G.; Cohen, C.J.; Segal, D.; Kirkin, A.F.; Reiter, Y. Recombinant human single-chain MHC-peptide complexes made from E. coli by in vitro refolding: Functional single-chain MHC-peptide complexes and tetramers with tumor associated antigens. Eur. J. Immunol. 2000, 30, 3522–3532, doi:10.1002/1521-4141(2000012)30:12<3522::AID-IMMU3522>3.0.CO;2-D.
[23]
Garboczi, D.N.; Hung, D.T.; Wiley, D.C. HLA-A2-peptide complexes: Refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. Proc. Natl. Acad. Sci. USA 1992, 89, 3429–3433, doi:10.1073/pnas.89.8.3429.
[24]
Denkberg, G.; Cohen, C.J.; Reiter, Y. Critical role for CD8 in binding of mhc tetramers to TCR: CD8 antibodies block specific binding of human tumor-specific MHC-peptide tetramers to TCR. J. Immunol. 2001, 167, 270–276.
[25]
Abastado, J.P.; Darche, S.; Jouin, H.; Delarbre, C.; Gachelin, G.; Kourilsky, P. A monoclonal antibody recognizes a subset of the H-2Dd mouse major class I antigens. Res. Immunol. 1989, 140, 581–594, doi:10.1016/0923-2494(89)90121-1.
[26]
Aharoni, R.; Teitelbaum, D.; Arnon, R.; Puri, J. Immunomodulation of experimental allergic encephalomyelitis by antibodies to the antigen-Ia complex. Nature 1991, 351, 147–150, doi:10.1038/351147a0.
[27]
Biddison, W.E.; Turner, R.V.; Gagnon, S.J.; Lev, A.; Cohen, C.J.; Reiter, Y. Tax and M1 peptide/HLA-A2-specific fabs and T cell receptors recognize nonidentical structural features on peptide/HLA-A2 complexes. J. Immunol. 2003, 171, 3064–3074.
[28]
Catipovic, B.; Dal Porto, J.; Mage, M.; Johansen, T.E.; Schneck, J.P. Major histocompatibility complex conformational epitopes are peptide specific. J. Exp. Med. 1992, 176, 1611–1618, doi:10.1084/jem.176.6.1611.
[29]
Chames, P.; Hufton, S.E.; Coulie, P.G.; Uchanska-Ziegler, B.; Hoogenboom, H.R. Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library. Proc. Natl. Acad. Sci. USA 2000, 97, 7969–7974, doi:10.1073/pnas.97.14.7969.
[30]
Cohen, C.J.; Denkberg, G.; Lev, A.; Epel, M.; Reiter, Y. Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: New tools to study antigen presentation and TCR-peptide-MHC interactions. J. Mol. Recognit. 2003, 16, 324–332, doi:10.1002/jmr.640.
[31]
Cohen, C.J.; Hoffmann, N.; Farago, M.; Hoogenboom, H.R.; Eisenbach, L.; Reiter, Y. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Cancer Res. 2002, 62, 5835–5844.
[32]
Cohen, C.J.; Sarig, O.; Yamano, Y.; Tomaru, U.; Jacobson, S.; Reiter, Y. Direct phenotypic analysis of human MHC class I antigen presentation: Visualization, quantitation, and in situ detection of human viral epitopes using peptide-specific, MHC-restricted human recombinant antibodies. J. Immunol. 2003, 170, 4349–4361.
[33]
Dadaglio, G.; Nelson, C.A.; Deck, M.B.; Petzold, S.J.; Unanue, E.R. Characterization and quantitation of peptide-MHC complexes produced from hen egg lysozyme using a monoclonal antibody. Immunity 1997, 6, 727–738, doi:10.1016/S1074-7613(00)80448-3.
[34]
Day, P.M.; Yewdell, J.W.; Porgador, A.; Germain, R.N.; Bennink, J.R. Direct delivery of exogenous MHC class I molecule-binding oligopeptides to the endoplasmic reticulum of viable cells. Proc. Natl. Acad. Sci. USA 1997, 94, 8064–8069, doi:10.1073/pnas.94.15.8064.
[35]
Denkberg, G.; Cohen, C.J.; Lev, A.; Chames, P.; Hoogenboom, H.R.; Reiter, Y. Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity. Proc. Natl. Acad. Sci. USA 2002, 99, 9421–9426.
[36]
Froscher, B.G.; Klinman, N.R. Immunization with SV40-transformed cells yields mainly MHC-restricted monoclonal antibodies. J. Exp. Med. 1986, 164, 196–210, doi:10.1084/jem.164.1.196.
[37]
Held, G.; Matsuo, M.; Epel, M.; Gnjatic, S.; Ritter, G.; Lee, S.Y.; Tai, T.Y.; Cohen, C.J.; Old, L.J.; Pfreundschuh, M.; et al. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments. Eur. J. Immunol. 2004, 34, 2919–2929, doi:10.1002/eji.200425297.
[38]
Hogquist, K.A.; Grandea, A.G., 3rd; Bevan, M.J. Peptide variants reveal how antibodies recognize major histocompatibility complex class I. Eur. J. Immunol. 1993, 23, 3028–3036, doi:10.1002/eji.1830231145.
[39]
Krogsgaard, M.; Wucherpfennig, K.W.; Cannella, B.; Hansen, B.E.; Svejgaard, A.; Pyrdol, J.; Ditzel, H.; Raine, C.; Engberg, J.; Fugger, L. Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex. J. Exp. Med. 2000, 191, 1395–1412, doi:10.1084/jem.191.8.1395.
[40]
Lev, A.; Denkberg, G.; Cohen, C.J.; Tzukerman, M.; Skorecki, K.L.; Chames, P.; Hoogenboom, H.R.; Reiter, Y. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit. Cancer Res. 2002, 62, 3184–3194.
[41]
Polakova, K.; Plaksin, D.; Chung, D.H.; Belyakov, I.M.; Berzofsky, J.A.; Margulies, D.H. Antibodies directed against the MHC-I molecule H-2Dd complexed with an antigenic peptide: Similarities to a t cell receptor with the same specificity. J. Immunol. 2000, 165, 5703–5712.
[42]
Porgador, A.; Yewdell, J.W.; Deng, Y.; Bennink, J.R.; Germain, R.N. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 1997, 6, 715–726, doi:10.1016/S1074-7613(00)80447-1.
[43]
Reiter, Y.; Di Carlo, A.; Fugger, L.; Engberg, J.; Pastan, I. Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to major histocompatibility complex/peptide class I complexes with T cell receptor-like specificity. Proc. Natl. Acad. Sci. USA 1997, 94, 4631–4636, doi:10.1073/pnas.94.9.4631.
[44]
Rubin, B.; Malissen, B.; Jorgensen, P.N.; Zeuthen, J. Recognition of insulin on MHC-class-II-expressing l929 cells by antibody and T cells. Res. Immunol. 1989, 140, 67–74, doi:10.1016/0923-2494(89)90007-2.
[45]
Tamminen, W.L.; Wraith, D.; Barber, B.H. Searching for MHC-restricted anti-viral antibodies: Antibodies recognizing the nucleoprotein of influenza virus dominate the serological response of c57bl/6 mice to syngeneic influenza-infected cells. Eur. J. Immunol. 1987, 17, 999–1006, doi:10.1002/eji.1830170716.
[46]
Uchanska-Ziegler, B.; Nossner, E.; Schenk, A.; Ziegler, A.; Schendel, D.J. Soluble T cell receptor-like properties of an HLA-B35-specific monoclonal antibody (TU165). Eur. J. Immunol. 1993, 23, 734–738, doi:10.1002/eji.1830230325.
[47]
Wylie, D.E.; Sherman, L.A.; Klinman, N.R. Participation of the major histocompatibility complex in antibody recognition of viral antigens expressed on infected cells. J. Exp. Med. 1982, 155, 403–414, doi:10.1084/jem.155.2.403.
[48]
Yamano, Y.; Cohen, C.J.; Takenouchi, N.; Yao, K.; Tomaru, U.; Li, H.C.; Reiter, Y.; Jacobson, S. Increased expression of human t lymphocyte virus type I (HTLV-I) Tax11-19 peptide-human histocompatibility leukocyte antigen A*201 complexes on CD4+ CD25+ T cells detected by peptide-specific, major histocompatibility complex-restricted antibodies in patients with HTLV-I-associated neurologic disease. J. Exp. Med. 2004, 199, 1367–1377, doi:10.1084/jem.20032042.
[49]
Zehn, D.; Cohen, C.J.; Reiter, Y.; Walden, P. Extended presentation of specific MHC-peptide complexes by mature dendritic cells compared to other types of antigen-presenting cells. Eur. J. Immunol. 2004, 34, 1551–1560, doi:10.1002/eji.200324355.
[50]
Zhong, G.; Reis e Sousa, C.; Germain, R.N. Production, specificity, and functionality of monoclonal antibodies to specific peptide-major histocompatibility complex class II complexes formed by processing of exogenous protein. Proc. Natl. Acad. Sci. USA 1997, 94, 13856–13861, doi:10.1073/pnas.94.25.13856.
[51]
Benhar, I. Biotechnological applications of phage and cell display. Biotechnol. Adv. 2001, 19, 1–33, doi:10.1016/S0734-9750(00)00054-9.
[52]
de Haard, H.J.; van Neer, N.; Reurs, A.; Hufton, S.E.; Roovers, R.C.; Henderikx, P.; de Bruine, A.P.; Arends, J.W.; Hoogenboom, H.R. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J. Biol. Chem. 1999, 274, 18218–18230, doi:10.1074/jbc.274.26.18218.
[53]
Griffiths, A.D.; Williams, S.C.; Hartley, O.; Tomlinson, I.M.; Waterhouse, P.; Crosby, W.L.; Kontermann, R.E.; Jones, P.T.; Low, N.M.; Allison, T.J.; et al. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 1994, 13, 3245–3260.
Chames, P.; Willemsen, R.A.; Rojas, G.; Dieckmann, D.; Rem, L.; Schuler, G.; Bolhuis, R.L.; Hoogenboom, H.R. TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity. J. Immunol. 2002, 169, 1110–1118.
[56]
Stewart-Jones, G.; Wadle, A.; Hombach, A.; Shenderov, E.; Held, G.; Fischer, E.; Kleber, S.; Nuber, N.; Stenner-Liewen, F.; Bauer, S.; et al. Rational development of high-affinity T-cell receptor-like antibodies. Proc. Natl. Acad. Sci. USA 2009, 106, 5784–5788, doi:10.1073/pnas.0901425106.
[57]
Michaeli, Y.; Denkberg, G.; Sinik, K.; Lantzy, L.; Chih-Sheng, C.; Beauverd, C.; Ziv, T.; Romero, P.; Reiter, Y. Expression hierarchy of T cell epitopes from melanoma differentiation antigens: Unexpected high level presentation of tyrosinase-HLA-A2 complexes revealed by peptide-specific, MHC-restricted, TCR-like antibodies. J. Immunol. 2009, 182, 6328–6341, doi:10.4049/jimmunol.0801898.
[58]
Denkberg, G.; Klechevsky, E.; Reiter, Y. Modification of a tumor-derived peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide complex: Probing with TCR-like recombinant antibodies. J. Immunol. 2002, 169, 4399–4407.
[59]
Klechevsky, E.; Gallegos, M.; Denkberg, G.; Palucka, K.; Banchereau, J.; Cohen, C.; Reiter, Y. Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts. Cancer Res. 2008, 68, 6360–6367, doi:10.1158/0008-5472.CAN-08-0928.
[60]
Cloutier, S.M.; Couty, S.; Terskikh, A.; Marguerat, L.; Crivelli, V.; Pugnieres, M.; Mani, J.C.; Leisinger, H.J.; Mach, J.P.; Deperthes, D. Streptabody, a high avidity molecule made by tetramerization of in vivo biotinylated, phage display-selected scFV fragments on streptavidin. Mol. Immunol. 2000, 37, 1067–1077, doi:10.1016/S0161-5890(01)00023-2.
[61]
Makler, O.; Oved, K.; Netzer, N.; Wolf, D.; Reiter, Y. Direct visualization of the dynamics of antigen presentation in human cells infected with cytomegalovirus revealed by antibodies mimicking TCR specificity. Eur. J. Immunol. 2010, 40, 1552–1565, doi:10.1002/eji.200939875.
[62]
Denkberg, G.; Lev, A.; Eisenbach, L.; Benhar, I.; Reiter, Y. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen. J. Immunol. 2003, 171, 2197–2207.
Wittman, V.P.; Woodburn, D.; Nguyen, T.; Neethling, F.A.; Wright, S.; Weidanz, J.A. Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death. J. Immunol. 2006, 177, 4187–4195.
[65]
Sastry, K.S.R.; Too, C.T.; Kaur, K.; Gehring, A.J.; Low, L.; Javiad, A.; Pollicino, T.; Li, L.; Kennedy, P.T.F.; Lopatin, U.; et al. Targeting hepatitis B virus-infected cells with a T-cell receptor-like antibody. J. Virol. 2011, 85, 1935–1942, doi:10.1128/JVI.01990-10.
[66]
Herschhorn, A.; Marasco, W.A.; Hizi, A. Antibodies and lentiviruses that specifically recognize a T cell epitope derived from HIV-1 Nef protein and presented by HLA-C. J. Immunol. 2010, 185, 7623–7632, doi:10.4049/jimmunol.1001561.
[67]
Bernardeau, K.G.S.; David, G.; Ruellan, A.L.; Devys, A.; Barbet, J.; Bonneville, M.; Chérel, M.; Davodeau, F. Assessment of CD8 involvement in T cell clone avidity by direct measurement of HLA-A2/MAGE3 complex density using a high-affinity TCR like monoclonal antibody. Eur. J. Immunol. 2005, 35, 2864–2875, doi:10.1002/eji.200526307.
[68]
Verma, B.; Neethling, F.A.; Caseltine, S.; Fabrizio, G.; Largo, S.; Duty, J.A.; Tabaczewski, P.; Weidanz, J.A. TCR mimic monoclonal antibody targets a specific peptide/hla class I complex and significantly impedes tumor growth in vivo using breast cancer models. J. Immunol. 2010, 184, 2156–2165, doi:10.4049/jimmunol.0902414.
[69]
Bronner, V.; Denkberg, G.; Peled, M.; Elbaz, Y.; Zahavi, E.; Kasoto, H.; Reiter, Y.; Notcovich, A.; Bravman, T. Therapeutic antibodies: Discovery and development using the ProteOn XPR3 biosensor interaction array system. Anal. Biochem. 2010, 406, 147–156, doi:10.1016/j.ab.2010.07.005.
[70]
Weiner, L.M.; Surana, R.; Wang, S. Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 2010, 10, 317–327, doi:10.1038/nri2744.
[71]
Dahan, R.; Reiter, Y. T-cell-receptor-like antibodies—Generation, function and applications. Expert Rev. Mol. Med. 2012, 14, e6, doi:10.1017/erm.2012.2.
[72]
Cartron, G.; Dacheux, L.; Salles, G.; Solal-Celigny, P.; Bardos, P.; Colombat, P.; Watier, H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99, 754–758, doi:10.1182/blood.V99.3.754.
[73]
Clynes, R.A.; Towers, T.L.; Presta, L.G.; Ravetch, J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 2000, 6, 443–446, doi:10.1038/74704.
[74]
Edwards, M.S.; Chadda, S.D.; Zhao, Z.; Barber, B.L.; Sykes, D.P. A systematic review of treatment guidelines for metastatic colorectal cancer. Colorectal Dis. 2012, 14, e31–e47, doi:10.1111/j.1463-1318.2011.02765.x.
[75]
Kreitman, R.J. Immunotoxins for targeted cancer therapy. AAPS J. 2006, 8, E532–E551, doi:10.1208/aapsj080363.
Litvak-Greenfeld, D.; Benhar, I. Risks and untoward toxicities of antibody-based immunoconjugates. Adv. Drug Deliv. Rev. 2012, 64, 1782–1799, doi:10.1016/j.addr.2012.05.013.
[79]
Falnes, P.O.; Sandvig, K. Penetration of protein toxins into cells. Curr. Opin. Cell Biol. 2000, 12, 407–413, doi:10.1016/S0955-0674(00)00109-5.
[80]
Menestrina, G.; Schiavo, G.; Montecucco, C. Molecular mechanisms of action of bacterial protein toxins. Mol. Aspects Med. 1994, 15, 79–193, doi:10.1016/0098-2997(94)90043-4.
[81]
Chiron, M.F.; Fryling, C.M.; FitzGerald, D. Furin-mediated cleavage of pseudomonas exotoxin-derived chimeric toxins. J. Biol. Chem. 1997, 272, 31707–31711.
[82]
Williams, D.P.; Wen, Z.; Watson, R.S.; Boyd, J.; Strom, T.B.; Murphy, J.R. Cellular processing of the interleukin-2 fusion toxin DAB486-IL-2 and efficient delivery of diphtheria fragment A to the cytosol of target cells requires Arg194. J. Biol. Chem. 1990, 265, 20673–20677.
[83]
Carroll, S.F.; Collier, R.J. Active site of pseudomonas aeruginosa exotoxin a. Glutamic acid 553 is photolabeled by nad and shows functional homology with glutamic acid 148 of diphtheria toxin. J. Biol. Chem. 1987, 262, 8707–8711.
[84]
Van Ness, B.G.; Howard, J.B.; Bodley, J.W. Adp-ribosylation of elongation factor 2 by diphtheria toxin. Isolation and properties of the novel ribosyl-amino acid and its hydrolysis products. J. Biol. Chem. 1980, 255, 10717–10720.
[85]
Kreitman, R.J. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs 2009, 23, 1–13, doi:10.2165/00063030-200923010-00001.
[86]
Seetharam, S.; Chaudhary, V.K.; FitzGerald, D.; Pastan, I. Increased cytotoxic activity of pseudomonas exotoxin and two chimeric toxins ending in KDEL. J. Biol. Chem. 1991, 266, 17376–17381.
[87]
Denkberg, G.; Lev, A.; Eisenbach, L.; Benhar, I.; Reiter, Y. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen. J. Immunol. 2003, 171, 2197–2207.
[88]
Epel, M.; Carmi, I.; Soueid-Baumgarten, S.; Oh, S.K.; Bera, T.; Pastan, I.; Berzofsky, J.; Reiter, Y. Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies. Eur. J. Immunol. 2008, 38, 1706–1720, doi:10.1002/eji.200737524.
[89]
Cohen, C.J.; Denkberg, G.; Segal, D.; Reiter, Y. Generation of recombinant immunotoxins for specific targeting of tumor-related peptides presented by MHC molecules. Methods Mol. Biol. 2003, 207, 269–282.
[90]
Ghetie, M.A.; Tucker, K.; Richardson, J.; Uhr, J.W.; Vitetta, E.S. The antitumor activity of an anti-CD22 immunotoxin in scid mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin. Blood 1992, 80, 2315–2320.
[91]
Tsutsumi, Y.; Onda, M.; Nagata, S.; Lee, B.; Kreitman, R.J.; Pastan, I. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc. Natl. Acad. Sci. USA 2000, 97, 8548–8553, doi:10.1073/pnas.140210597.
[92]
Ji, C.; Sastry, K.S.; Tiefenthaler, G.; Cano, J.; Tang, T.; Ho, Z.Z.; Teoh, D.; Bohini, S.; Chen, A.; Sankuratri, S.; et al. Targeted delivery of interferon-α to hepatitis B virus-infected cells using T-cell receptor-like antibodies. Hepatology 2012, 56, 2027–2038, doi:10.1002/hep.25875.
